We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

TScan Therapeutics Inc (TCRX) USD0.0001

Sell:$6.18 Buy:$7.44 Change: $0.14 (1.97%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$6.18
Buy:$7.44
Change: $0.14 (1.97%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$6.18
Buy:$7.44
Change: $0.14 (1.97%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

Contact details

Address:
880 Winter Street
WALTHAM
02451
United States
Telephone:
+1 (857) 3999500
Website:
https://www.tscan.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TCRX
ISIN:
US89854M1018
Market cap:
$358.15 million
Shares in issue:
50.30 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Gavin Macbeath
    Chief Executive Officer
  • Jason Amello
    Principal Financial Officer, Principal Accounting Officer, Treasurer
  • Ann Hargraves
    Senior Vice President - Human Resources
  • Shrikanta Chattopadhyay
    Senior Vice President - Medical, Translational Medicine
  • Ray Lockard
    Senior Vice President - Technical Operations and Quality
  • Justin McCue
    Chief Technology Officer
  • Debora Barton
    Chief Medical Officer
  • Zoran Zdraveski
    Company Secretary, Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.